Vivienne Theobald

Vivienne Theobald

Auto-generated profile, based on publicly available information

Vivienne Theobald

Heidelberg University, Medical Faculty Heidelberg, Department of Anesthesiology, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2025 in Journal of Infection
Verified
Journal Article
Open access
VTVivienne Theobald
Vivienne Theobald
FBFrank Bloos
Frank Bloos
MBMichael Bauer
Michael Bauer
TBThorsten Brenner
Thorsten Brenner
MFMaik von der Forst
Maik von der Forst
MDMaximilian Dietrich
Maximilian Dietrich
Sepsis is a life-threatening condition and many biomarkers for diagnosing and treatment guidance have been investigated in recent years. However, new ones are emerging almost daily, only few markers with diagnostic value have passed to entered clinical routine application. Delta-like canonical Notch ligand-1 (DLL-1) seems to be a potential contributor in the differentiation between sepsis and non-septic infection. Its role for clinical application and potential septic outcome prediction is yet unclear. This study is a secondary analysis of data and DLL-1 measurements from plasma samples obtained in the SISPCT trial. Primary objective of this explorative study was to investigate the difference of DLL-1 values between patients with sepsis and septic shock. Secondary objectives were the differences in DLL-1 levels in patients with different blood culture results, with infections caused by different pathogens, by origin of infection and disease severity. Furthermore, the study investigated the use of DLL-1 for in-hospital and intensive care unit (ICU) mortality prediction. Therefore, data from 1.027 patients were analyzed. DLL-1 values were significantly higher in patients with septic shock than in septic patients (13,003 ± 7695 pg/mL and 9257 ± 4188 pg/mL, p<0.001). Patients with abdominal infections, primary bacteremia or surgical wound infections exhibited the highest DLL-1 values. In addition, patients with gram-negative pathogens had significantly higher DLL-1 levels than those with specific gram-positive pathogens or negative blood cultures (p<0.001). Infections caused by Escherichia coli, Enterobacterales, and Staphylococcus aureus were associated with the highest DLL-1 levels (18,341 pg/mL, (12,968; 23,250), 21,556 pg/mL (14,386; 30,939) and 16,352 pg/mL (11,905; 25,853), respectively). DLL-1 levels correlated with increasing SOFA scores and demonstrated predictive value for in-hospital and ICU mortality, with an AUC of 0.7, outperforming lactate and procalcitonin. Delta-like canonical Notch ligand-1 (DLL-1) is increased in septic shock compared to sepsis. Its elevation appears to be dependent on the infection focus, the triggering pathogen and the disease severity. Furthermore, it has a predictive value for mortality.

1 April 2023 in Pulmonary Circulation
Verified
Journal Article
Open access
VTVivienne Theobald
Vivienne Theobald
EGEkkehard Grünig
Ekkehard Grünig
NBNicola Benjamin
Nicola Benjamin
HSHans‐Jürgen Seyfarth
Hans‐Jürgen Seyfarth
MHMichael Halank
Michael Halank
CEChristina A. Eichstaedt
Christina A. Eichstaedt
Iron deficiency is common in idiopathic and heritable pulmonary arterial hypertension patients (I/HPAH). A previous report suggested a dysregulation of the iron hormone hepcidin, which is controlled by BMP/SMAD signaling involving the bone morphogenetic protein receptor 2 (BMPR‐II). Pathogenic variants in the BMPR2 gene are the most common cause of HPAH. Their effect on patients' hepcidin levels has not been investigated. The aim of this study was to assess whether iron metabolism and regulation of the iron regulatory hormone hepcidin was disturbed in I/HPAH patients with and without a pathogenic variant in the gene BMPR2 compared to healthy controls. In this explorative, cross‐sectional study hepcidin serum levels were quantified by enzyme‐linked immunosorbent assay. We measured iron status, inflammatory parameters and hepcidin modifying proteins such as IL6, erythropoietin, and BMP2, BMP6 in addition to BMPR‐II protein and mRNA levels. Clinical routine parameters were correlated with hepcidin levels. In total 109 I/HPAH patients and controls, separated into three groups, 23 BMPR2 variant‐carriers, 56 BMPR2 noncarriers and 30 healthy controls were enrolled. Of these, 84% had iron deficiency requiring iron supplementation. Hepcidin levels were not different between groups and corresponded to the degree of iron deficiency. The levels of IL6, erythropoietin, BMP2, or BMP6 showed no correlation with hepcidin expression. Hence, iron homeostasis and hepcidin regulation was largely independent from these parameters. I/HPAH patients had a physiologically normal iron regulation and no false elevation of hepcidin levels. Iron deficiency was prevalent albeit independent of pathogenic variants in the BMPR2 gene.

28 February 2020 in Pneumologie
Verified
Conference Paper
Closed access
PXPanagiota Xanthouli
Panagiota Xanthouli
MKM Koegler
M Koegler
NBNicola Benjamin
Nicola Benjamin
LFL Fischer
L Fischer
BEBenjamin Egenlauf
Benjamin Egenlauf
EGE Grünig
E Grünig
Background: The current guidelines for pulmonary arterial hypertension (PAH) propose risk stratification into three groups using clinical parameters and the estimated one-year survival. This study sought to analyse whether this risk stratification is also useful in patients with PAH and comorbidities. Methods: In this study patients with invasively diagnosed PAH with or without comorbidities were included. Uni- and multivariate analysis were employed for identification of factors predicting survival and time to first clinical worsening (TTCW) in both groups. Risk stratification parameters included 6-minute walking distance (6MWD), right atrial (RA) area, WHO-functional class (FC) and NTproBNP. Results: In total 150 patients were enrolled into the study, 8 were excluded due to missing values. Of the remaining 142 patients 90 were diagnosed as PAH without and 52 with comorbidities. All patients received targeted PAH therapy and were followed for 3.3 ± 2.4 years. According to the ESC/ERS risk stratification survival and TTCW were significantly associated with reduced 6MWD (p = 0.019; p = 0.031), elevated NTproBNP (p = 0.032; p = 0.002), WHO-FC (p = 0.016; p = 0.079) and RA area (p = 0.013; p = 0.034) in the univariate Cox Regression analysis in PAH without comorbidities. In the multivariate analysis, 6MWD was an independent predictor for survival (p = 0.002) and WHO-FC for TTCW (p = 0.001). These parameters had no significant association with survival and TTCW in PAH with comorbidities. Average risk score was significantly associated with survival (p = 0.001) and TTCW (p = 0.013) in PAH but not in PAH with comorbidities (both p > 0.05; [Fig. 1]). Conclusion: Risk stratification based on ESC/ERS-guidelines could only be confirmed in patients without comorbidities but not in patients with PAH and comorbidities. The data of this study suggest, that a different risk stratification needs to be applied to PAH patients with comorbidities. Further studies are needed to confirm these results.

28 February 2020 in Pneumologie
Verified
Conference Paper
Closed access
VTV Theobald
V Theobald
NBNicola Benjamin
Nicola Benjamin
BEBenjamin Egenlauf
Benjamin Egenlauf
HGH Gall
H Gall
EGE Grünig
E Grünig
CEChristina A. Eichstaedt
Christina A. Eichstaedt
Background: Iron deficiency is common in pulmonary arterial hypertension (PAH) patients and leads to a significantly reduced 6-minute walking distance (6MWD), a higher WHO functional class and greater mortality. Iron metabolism is regulated via the hormone hepcidin, which is upregulated by the binding of bone morphogenetic proteins, to the bone morphogenetic protein receptor 2 (BMPR2). Hepcidin is increased in iron deficient idiopathic and hereditary PAH (I/HPAH) patients falsely signaling iron abundance. At the same time, 25% of IPAH and 85% of HPAH patients carry pathogenic variants in the BMPR2 gene. Objective: We aim to investigate the effect of an unbalanced BMPR2 pathway on iron metabolism and clinical parameters in BMPR2 mutation carriers and non-carriers. Methods: In this explorative cross-sectional study BMPR2 expression of 20 HPAH, 40 IPAH patients and 20 healthy controls will be measured by quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA). The primary endpoint will be the relationship between hepcidin and BMPR2 expression in mutation carriers and non-carriers. Secondary endpoints include iron related parameters, expression level of BMP6, as well as clinical parameters including 6MWD, echocardiographic and haemodynamic values. Additionally, iron staining of lung tissue from HPAH, IPAH patients and controls will reveal information about intracellular iron concentrations. Current status: So far 53 study participants have been successfully enrolled. The expression levels remain to be analysed jointly once recruitment has terminated. Hypothesis: We hypothesize that BMPR2 mutation carriers with lower mRNA expression of BMPR2 show higher hepcidin levels and will suffer from more severe iron deficiency than non-BMPR2 mutation carriers and healthy controls with slightly reduced or normal expression rates, respectively.

28 February 2020 in Pneumologie
Verified
Conference Paper
Closed access
PXPanagiota Xanthouli
Panagiota Xanthouli
SJS Jordan
S Jordan
NMN Milde
N Milde
AMAm Marra
Am Marra
NBNorbert Blank
Norbert Blank
ODOliver Distler
Oliver Distler
Background: In this study we investigated the impact of the new hemodynamic definition of pulmonary hypertension (PH) with mean pulmonary arterial pressure (mPAP) > 20 mmHg, pulmonary arterial wedge pressure ≤ 15 mmHg and pulmonary vascular resistance (PVR) ≥ 3 WU, as proposed by the 6th PH World Symposium in patients with systemic sclerosis (SSc). Methods: In consecutive SSc-patients who were prospectively screened for PH including right heart catheterization in 2 PAH/SSc centers (Heidelberg and Zurich) hemodynamic and clinical variables have been reassessed according to the new PAH-definition. Long-term follow-up and survival analysis have been performed. Patients with significant lung or left heart disease were excluded from comparative analyses. Results: The final dataset included 284 SSc-patients who have been followed for 3.7 ± 3.7 (median 3.4) years, 146 patients (49.2%) had mPAP ≤ 20 mmHg, 19.3% had mildly elevated mPAP (21 – 24 mmHg) and 29.4% had mPAP ≥ 25 mmHg ([Fig. 1]). In the group of mildly elevated mPAP, only four patients (1.4% of the whole SSc-cohort) had PVR-values ≥ 3WU and could be reclassified as manifest SSc-APAH according to the new definition. If a threshold for PVR ≥ 2WU would be used, 28 (9,85%) patients would have been newly diagnosed with PAH ([Fig. 2]). These patients (mPAP 21 – 24 mmHg, PVR ≥ 2WU) had already an early pulmonary vascular disease with reduced 6-minute walking distance (p < 0.001), tricuspid annular plane systolic excursion (p = 0.004), pulmonary arterial compliance (p < 0.001) and long-term survival (p = 0.002) ([Fig. 3]) compared to those with normal hemodynamic values. Conclusions: The new hemodynamic PAH definition did not have a significant impact on the diagnosis of PH. The data of this study suggest, that a PVR threshold > 3WU may be too high and significantly impairs the possibility of an early diagnosis with significant impact on survival ([Fig. 3]).